Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Etaracizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Etaracizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Etaracizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Etaracizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Etaracizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Etaracizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Etaracizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Etaracizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Etaracizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Etaracizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Etaracizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Etaracizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Etaracizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Etaracizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Etaracizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Etaracizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Etaracizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Etaracizumab. |
| Equol | Equol may increase the thrombogenic activities of Etaracizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Etaracizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Etaracizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Etaracizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Etaracizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Etaracizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Etaracizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Etaracizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Etaracizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Etaracizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Etaracizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Etaracizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Etaracizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Etaracizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Etaracizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Etaracizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Etaracizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etaracizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Etaracizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Etaracizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Etaracizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Etaracizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Etaracizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Etaracizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Etaracizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etaracizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Etaracizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etaracizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Etaracizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Etaracizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etaracizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Etaracizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Etaracizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Etaracizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etaracizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Etaracizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Etaracizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Etaracizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Etaracizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Etaracizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Etaracizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Etaracizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Etaracizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Etaracizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Etaracizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Etaracizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Etaracizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Etaracizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Etaracizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Etaracizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Etaracizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Etaracizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Etaracizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Etaracizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Etaracizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Etaracizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Etaracizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Etaracizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Etaracizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Etaracizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Etaracizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Etaracizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Etaracizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Etaracizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Etaracizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Etaracizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Etaracizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Etaracizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Etaracizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Etaracizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Etaracizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Etaracizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Etaracizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Etaracizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Etaracizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Etaracizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Etaracizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Etaracizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Etaracizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Etaracizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Etaracizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Etaracizumab. |